Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials-Reference-Cited by-同舟云学术

Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials

Published:2016-09-29 Issue:1 Volume:19 Page:142-147
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Tang Huilin¹²³,Cui Wei⁴,Li Dandan⁵,Wang Tiansheng⁶,Zhang Jingjing⁷,Zhai Suodi¹,Song Yiqing²³

Affiliation:

1. Department of Pharmacy; Peking University Third Hospital; Beijing China

2. Department of Epidemiology, Richard M. Fairbanks School of Public Health; Indiana University; Indianapolis Indiana

3. Center for Pharmacoepidemiology, Richard M. Fairbanks School of Public Health; Indiana University; Indianapolis Indiana

4. Department of Endocrinology and Metabolism, The First Affiliated Hospital of Xi'an Jiaotong University; Xi'an Jiaotong University Health Science Center; Xi'an China

5. Department of Pharmacy, Beijing Friendship Hospital; Capital Medical University; Beijing China

6. Department of Pharmacy Administration and Clinical Pharmacy; Peking University Health Science Center; Beijing China

7. Division of Nephrology, Sidney Kimmel Medical College; Thomas Jefferson University; Philadelphia Pennsylvania

Funder

Indiana University Health-Indiana University School of Medicine Strategic Research Initiative

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12785/fullpdf

Reference20 articles.

1. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug;Idris;Diabetes Obes Metab,2009

2. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes;Inzucchi;Diabetes Care,2015

3. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis;Zaccardi;Diabetes Obes Metab,2016

4. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis;Vasilakou;Ann Intern Med,2013

5. Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin: rationale and evidences;Singh;Expert Rev Clin Pharmacol,2016

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative risk of infection of medications used for type 2 diabetes;Expert Opinion on Drug Safety;2024-09-11

2. Open questions on basal insulin therapy in T2D: a Delphi consensus;Acta Diabetologica;2024-05-20

3. Balancing Risks and Benefits: Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis;Metabolites;2024-03-13

4. Diabetes and Ramadan fasting;BIDE' s Diabetes Desk Book;2024

5. UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE;BMC Nephrology;2023-10-25